Page 48 - Read Online

Page 158 Lotz et al. Cancer Drug Resist 2020;3:149-60 I http://dx.doi.org/10.20517/cdr.2019.114

cells depleting the activity of DNA topoisomerase II alpha. Genes Cells 2003;8:393-402.
4. Collins I, Weber A, Levens D. Transcriptional consequences of topoisomerase inhibition. Mol Cell Biol 2001;21:8437-51.
5. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001;70:369-413.
6. Clarke DJ, Azuma Y. Non-catalytic roles of the topoisomerase II C-terminal domain. Int J Mol Sci 2017;18.
7. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-50.
8. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase-Ii by trapping the
enzyme in the form of a closed protein clamp. Proc Natl Acad Sci U S A 1994;91:1781-5.
9. Wu CC, Li TK, Farh L, Lin LY, Lin TS, et al. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Science 2011;333:459-62.
10. Vassetzky YS, Alghisi GC, Gasser SM. DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays 1995;17:767-74.
11. Cicenas J, Zalyte E, Bairoch A, Gaudet P. Kinases and cancer. Cancers (Basel) 2018;10.
12. Han ZJ, Feng YH, Gu BH, Li YM, Chen H. The post-translational modification, SUMOylation, and cancer (review). Int J Oncol
2018;52:1081-94.
13. Saijo M, Enomoto T, Hanaoka F, Ui M. Purification and characterization of type II DNA topoisomerase from mouse Fm3a cells:
phosphorylation of topoisomerase-Ii and modification of its activity. Biochemistry 1990;29:583-90.
14. Mann M, Jensen ON. Proteomic analysis of post-translational modifications. Nat Biotechnol 2003;21:255-61.
15. Chen T, Sun Y, Ji P, Kopetz S, Zhang W. Topoisomerase IIalpha in chromosome instability and personalized cancer therapy. Oncogene
2015;34:4019-31.
16. Bedez C, Lotz C, Batisse C, Broeck AV, Stote RH, et al. Post-translational modifications in DNA topoisomerase 2α highlight the role of a
eukaryote-specific residue in the ATPase domain. Sci Rep 2018;8:9272.
17. Wells NJ, Fry AM, Guano F, Norbury C, Hickson ID. Cell cycle phase-specific phosphorylation of human topoisomerase II alpha.
Evidence of a role for protein kinase C. J Biol Chem 1995;270:28357-63.
18. Grozav AG, Chikamori K, Grabowski DR, Xu Y, Kinter M, et al. Casein kinase I delta/epsilon isoforms phosphorylate serine 1106 in the
catalytic domain of human topoisomerase II alpha. Cancer Res 2006;47.
19. Shapiro PS, Whalen AM, Tolwinski NS, Wilsbacher J, Froelich-Ammon SJ, et al. Extracellular signal-regulated kinase activates
topoisomerase II alpha through a mechanism independent of phosphorylation. Mol Cell Biol 1999;19:3551-60.
20. Adachi N, Miyaike M, Kato S, Kanamaru R, Koyama H, et al. Cellular distribution of mammalian DNA topoisomerase II is determined
by its catalytically dispensable C-terminal domain. Nucleic Acids Res 1997;25:3135-42.
21. Ishida R, Takashima R, Koujin T, Shibata M, Nozaki N, et al. Mitotic specific phosphorylation of serine-1212 in human DNA
topoisomerase II alpha. Cell Struct Funct 2001;26:215-26.
22. Devore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase c: effects on enzyme-
mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4’-(9-Acridinylamino) methane-sulfon-m-
anisidide. Cancer Res 1992;52:2156-61.
23. Plo I, Hernandez H, Kohlhagen G, Lautier D, Pommier Y, et al. Overexpression of the atypical protein kinase C reduces topoisomerase
II catalytic activity, cleavable complexes formation, and drug-induced cytotoxicity in monocytic U937 leukemia cells. J Biol Chem
2002;277:31407-15.
24. Chikamori K, Grabowski DR, Kinter M, Willard BB, Yadav S, et al. Phosphorylation of serine 1106 in the catalytic domain of
topoisomerase II alpha regulates enzymatic activity and drug sensitivity. J Biol Chem 2003;278:12696-702.
25. Shiozaki K, Yanagida M. Functional dissection of the phosphorylated termini of fission yeast DNA topoisomerase-II. J Cell Biol
1992;119:1023-36.
26. Luo KT, Yuan J, Chen JJ, Lou ZK. Topoisomerase IIalpha controls the decatenation checkpoint. Nat Cell Biol 2009;11:204-10.
27. Wells NJ, Addison CM, Fry AM, Ganapathi R, Hickson ID. Serine 1524 is a major site of phosphorylation on human topoisomerase II
alpha protein in vivo and is a substrate for casein kinase II in vitro. J Biol Chem 1994;269:29746-51.
28. Li H, Wang Y, Liu X. Plk1-dependent phosphorylation regulates functions of DNA topoisomerase II alpha in cell cycle progression. J
Biol Chem 2008;283:6209-21.
29. Qi XM, Hou SW, Lepp A, Li RS, Basir Z, et al. Phosphorylation and stabilization of topoisomerase II alpha protein by p38 gamma
mitogen-activated protein kinase sensitize breast cancer cells to its poisons. J Biol Chem 2011;286:35883-90.
30. Lane AB, Gimenez-Abian JF, Clarke DJ. A novel chromatin tether domain controls topoisomerase II alpha dynamics and mitotic
chromosome formation. J Cell Biol 2013;203:471-86.
31. Corbett AH, Fernald AW, Osheroff N. Protein kinase C modulates the catalytic activity of topoisomerase II by enhancing the rate of atp
hydrolysis: evidence for a common mechanism of regulation by phosphorylation. Biochemistry 1993;32:2090-7.
32. Corbett AH, Devore RF, Osheroff N. Effect of casein kinase-II-mediated phosphorylation on the catalytic cycle of topoisomerase II.
Regulation of enzyme activity by enhancement of ATP hydrolysis. J Biol Chem 1992;267:20513-8.
33. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M. Increased phosphorylation of DNA topoisomerase-II in etoposide-resistant mutants
of human cancer KB cells. Cancer Res 1991;51:3951-7.
34. Nakazawa N, Arakawa O, Ebe M, Yanagida M. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the
effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast. J Biol Chem 2019;294:3772-82.
35. Matsumoto Y, Takano H, Fojo T. Cellular adaptation to drug exposure: Evolution of the drug-resistant phenotype. Cancer Res
1997;57:5086-92.
36. Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC. Reduced phosphorylation of topoisomerase II in etoposide-resistant human